Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 14, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
June 29, 2020 07:15 ET
|
Kiniksa Pharmaceuticals, Ltd.
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy...
Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical Trial
June 18, 2020 08:02 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, June 18, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 03, 2020 08:00 ET
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy
May 21, 2020 06:30 ET
|
Shah Capital
RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two key patents related to its lead...
Bone Therapeutics traite les premiers patients de son étude pivot de phase III évaluant JTA-004 dans l’arthrose du genou
May 18, 2020 01:00 ET
|
Bone Therapeutics SA
Communiqué de presse Traitement des premiers patients suite à la reprise des activités cliniques à Hong-Kong Approbation de l’étude de phase III évaluant JTA-004 dans cinq pays sur les sept dans...
Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
May 18, 2020 01:00 ET
|
Bone Therapeutics SA
Press Release First patients treated following resumption of clinical activities in Hong Kong JTA-004 phase III study approved in five of seven territories Gosselies, Belgium, 18 May 2020, 7am...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
May 06, 2020 16:30 ET
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
March 05, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...